278 related articles for article (PubMed ID: 10100720)
21. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
[TBL] [Abstract][Full Text] [Related]
22. Protease activation and cleavage of poly(ADP-ribose) polymerase: an integral part of apoptosis in response to photodynamic treatment.
He J; Whitacre CM; Xue LY; Berger NA; Oleinick NL
Cancer Res; 1998 Mar; 58(5):940-6. PubMed ID: 9500454
[TBL] [Abstract][Full Text] [Related]
23. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
Kim R; Hirabayashi N; Nishiyama M; Jinushi K; Toge T; Okada K
Int J Cancer; 1992 Mar; 50(5):760-6. PubMed ID: 1312063
[TBL] [Abstract][Full Text] [Related]
24. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
Thomas HD; Calabrese CR; Batey MA; Canan S; Hostomsky Z; Kyle S; Maegley KA; Newell DR; Skalitzky D; Wang LZ; Webber SE; Curtin NJ
Mol Cancer Ther; 2007 Mar; 6(3):945-56. PubMed ID: 17363489
[TBL] [Abstract][Full Text] [Related]
25. ATP modulates poly(ADP-ribose) polymerase-1-facilitated topoisomerase I-linked DNA religation in the presence of camptothecin.
Park SY; Leung CH; Cheng YC
Mol Pharmacol; 2008 Jun; 73(6):1829-37. PubMed ID: 18349103
[TBL] [Abstract][Full Text] [Related]
26. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
27. Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Tentori L; Leonetti C; Muzi A; Dorio AS; Porru M; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Int J Oncol; 2013 Jul; 43(1):210-8. PubMed ID: 23653048
[TBL] [Abstract][Full Text] [Related]
28. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.
Wang Q; Li N; Wang X; Kim MM; Evers BM
Clin Cancer Res; 2002 Jun; 8(6):1940-7. PubMed ID: 12060639
[TBL] [Abstract][Full Text] [Related]
29. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
[TBL] [Abstract][Full Text] [Related]
30. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
31. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins.
Satoh TH; Surmacz TA; Nyormoi O; Whitacre CM
Biocell; 2003 Apr; 27(1):47-55. PubMed ID: 12847914
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
35. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
36. Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Cimmino G; Pepe S; Laus G; Chianese M; Prece D; Penitente R; Quesada P
Pharmacol Res; 2007 Jan; 55(1):49-56. PubMed ID: 17127074
[TBL] [Abstract][Full Text] [Related]
37. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.
Lesueur-Ginot L; Demarquay D; Kiss R; Kasprzyk PG; Dassonneville L; Bailly C; Camara J; Lavergne O; Bigg DC
Cancer Res; 1999 Jun; 59(12):2939-43. PubMed ID: 10383158
[TBL] [Abstract][Full Text] [Related]
38. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
[TBL] [Abstract][Full Text] [Related]
40. Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
Montariello D; Troiano A; Di Girolamo D; Beneke S; Calabrò V; Quesada P
Biochem Pharmacol; 2015 Apr; 94(3):212-9. PubMed ID: 25667043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
